LIDDS
0.11
SEK
+9.45 %
LIDDS
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+9.45%
-31.25%
-17.91%
-25.17%
+1.85%
-24.4%
-98.87%
-99.21%
-98.85%
liddspharma.com/en/investors
LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patent-protected and clinically tested drug delivery technology. The properties of the products form the basis of LIDDS 'technology platform for the development of injectable drug products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System and the company is headquartered in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LIDDS
Daily low / high price
0.1 / 0.11
SEK
Market cap
15.01M SEK
Turnover
1.23K SEK
Volume
12K
Financial calendar
Annual report
2025-02-20
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Daniel Lifveredson via bolag | 20.5 % | 20.5 % |
| Avanza Pension | 7.9 % | 7.9 % |
| Ove Högberg | 6.3 % | 6.3 % |
| Marita Högberg | 5.0 % | 5.0 % |
| Stefan Rehnmark | 4.9 % | 4.9 % |
| Wikow Venture | 4.5 % | 4.5 % |
| Torbjörn Browall, incl company-owned shares | 3.5 % | 3.5 % |
| Nordnet Pensionsförsäkring AB | 3.2 % | 3.2 % |
| Skyshire AB | 2.3 % | 2.3 % |
| Anders Bjartell | 1.9 % | 1.9 % |
ShowingAll content types
Nomination Committee appointed for the Annual General Meeting 2025 in LIDDS
LIDDS AB (publ) Delårsrapport januari – september 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools